IL-PROJECT44
30.6.2020 13:02:14 CEST | Business Wire | Press release
project44®, the global leader in advanced visibility for shippers and logistics service providers (LSP), today announced that it experienced a record-setting first half of 2020 with a 139% increase in bookings over the same period in 2019, with significant growth coming from global retailers, manufacturers, and distributors in North America and EMEA.
“project44’s momentum accelerates as we continue to unlock the strategic value of our platform with new innovative products, enterprise integrations and partnerships with tech leaders such as SAP and IBM, so together we can deliver greater business success for our customers,” said Jett McCandless, CEO and Founder of project44. “The last six months, when the economy was under immense pressure, have validated that real-time visibility has become an urgent must-have. As a result, project44 has emerged as both a category leader and the industry’s only global, multimodal visibility provider.”
“Our entire business philosophy is based on sustainability. By working with project44, we are looking to achieve even more supply chain sustainability and efficiency through seamless collaboration across our global logistics network,” said Anastasios Tasos Papadopoulos, Director Asset Management and Product Engineering Europe at IFCO Systems GmbH. "The real-time, accurate visibility data from across all modes and regions in a single platform helps us optimize our product flows and support our teams in managing of our shipments efficiently.”
In addition to exceptional business growth, project44 has achieved a number of important milestones, including:
Advanced Visibility Investment: In order to quickly meet the increasing demand for its products and services, project44 recently closed a round of funding which brings the total raised to over $50 million since Series C. The investment will enable the company to continue delivering on product innovation, rapid scalability of network breadth and depth, and global expansion.
Customer Traction : The company significantly increased its customer base in 2020, with key wins including Ferrero International, IFCO Systems GmbH, Lenovo, TIP Trailer Services, UniCarriers Americas Corporation, and more. As part of its rise to the dominant position, project44 is proud to deliver real-time transportation visibility to over 300 enterprise customers, which include the top 3 ranked companies on the Fortune 500 list, 2 of the 3 largest retailers in the world and 8 of the world’s top 10 freight brokerages, among others.
Geographic Expansion: project44’s business in EMEA has increased year-over-year by 303%. The customer community is now actively tracking over 21 million shipments in 120 countries, across North America, EMEA, LATAM, and APAC.
Product Innovation: project44 has quickly accelerated to become the only visibility company to provide one seamless global and multimodal experience . In May, the technology company added air freight and groupage visibility as well as expanded global ocean coverage to its platform. In addition to launching visibility into new modes and regions, project44 has continued to dominate the North American and European over the road markets with the announcement of multiple product advancements including an enhanced, predictive ETA model that calculates a shipment’s arrival status with 91% accuracy, built using data from over 3 million past shipments.
With Network Management Center™ (NMC), project44 continues to expand network onboarding capabilities to enable agility and operational efficiency through the entire transportation ecosystem, especially when fast time to value is critical. In addition to increasing the ways shippers and LSPs can connect to carriers and benefit from increased network stability , the application provides carriers with instant access to project44’s global customer base and, as a result, additional business opportunities.
Network Growth: As the only visibility provider to offer coverage across all modes of transportation, project44 delivers instant access to the most expansive and highest performing global network. This includes connections to more than 760 telematics/ ELD providers, representing 94% of the European market, and over 95% parcel coverage in North America and Europe. The company delivers 99.7% coverage of truckload and less-than-truckload carriers in North America and Europe with the majority consistently tracking over 90% compliance. It also provides ocean coverage for 85% of containers shipped globally and 100% coverage of the Class I and Class II railroads in North America. Earlier this year project44 announced the industry’s first service level agreement (SLA) , which ensures 90% of a shipper’s contracted full truckload carriers in North America and Europe go live within 30 days of commencing implementation.
Industry Recognition: project44 was recognized by SAP as Cloud Integration Partner of the Year for enabling global brands to build more agile supply chains. The winner was chosen based on recommendations from the SAP field, customer feedback, and performance indicators. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25 , a list of the most innovative companies across the freight industry.
“Every day thousands of companies trust DSV with their transport orders," said Simon H. Galsgaard, EVP at DSV, the world's fourth largest transport and logistics company. "Operational excellence and efficiency are critical to our business, and so is advanced real-time visibility. With project44, as our preferred visibility provider, we're achieving real-time visibility across the entire DSV fleet of own and subcontracted assets, for the benefit of our customers.”
Learn more about project44 or schedule a demo today.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates, and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. project44 has placed second, behind only Amazon, on FreightWaves’ 2020 Freight Tech 25, a list of the most innovative companies across the freight industry, and received the 2020 SAP® Pinnacle Award as the Cloud Partner Integration of the Year. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005151/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom